Biosyntrx

Biosyntrx is a science-based nutraceutical company specializing in the development of oral formulations for degenerative eye diseases. The company's product line targets conditions such as dry eye syndrome, age-related macular degeneration, and glaucoma through high-potency nutritional supplements. Founded by experts in ophthalmology and nutritional biochemistry, Biosyntrx focuses on addressing the underlying metabolic and oxidative factors contributing to ocular health decline. In May 2022, the company was acquired by OcuSoft, a major player in the ophthalmic industry, which integrated Biosyntrx's products into its broader eye care portfolio. The company remains a recognized name for evidence-based ocular nutrition.